Ventricular fibrillation induction and diffuse abnormal ST-segment response to ajmaline in a patient with apparent pre-existing dynamic right bundle branch block.

Abstract

OBJECTIVE:

ST-segment elevation in the right precordial electrocardiography (ECG) leads in Brugada syndrome (BS) can be unmasked by class I anti-arrhythmic drugs (sodium channel blockers) administration. It is still debated whether this ECG pattern is better explained by abnormal repolarization or ventricular conduction and depolarization. Conduction diseases can conceal type 1 BS-like ECG in standard V1-V3 leads. ECG alterations were found also in alternative leads. The role of electrophysiology study (EPS) in sudden cardiac death risk stratification remains controversial, and could depend on the phenotypic expression of the cardiac sodium channels disease.

CASE REPORT:

We describe unmasked diffuse J-point and ST-segment anomalies in peripheral and precordial ECG leads and ventricular fibrillation (VF) induction by EPS after ajmaline administration in a patient with pre-existing atypical right bundle branch block (RBBB) concealing subtle anomalies in standard V1-V3 leads. RBBB was influenced by the underlying BS-like ECG associating repolarization anomaly and pre-existing conduction disease. EPS induced VF when RBBB was associated with BS-like ECG, and failed to induce VF when RBBB was present alone.

CONCLUSIONS:

BS phenotype heterogeneity requires further studies to improve the knowledge of its pathophysiological mechanisms associated with conduction diseases in order to better identify an individual therapy and prognostic stratification.

• Authors: B L Nguyen, F Tufano, S De Angelis, F Tersigni, N Alessandri, P Brugada
• Journal: European review for medical and pharmacological sciences (Eur Rev Med Pharmacol Sci) Vol. 18 Issue 20 Pg. 3115-9 (Oct 2014) ISSN: 2284-0729 [Electronic] Italy
• PMID: 25392113 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-Arrhythmia Agents
• Ajmaline

Topics

• Ajmaline (therapeutic use)
• Anti-Arrhythmia Agents (therapeutic use)
• Brugada Syndrome (chemically induced, diagnosis, physiopathology)
• Bundle-Branch Block (diagnosis, drug therapy, physiopathology)
• Electrocardiography (methods)
• Humans
• Male
• Middle Aged
• Preexisting Condition Coverage
• Ventricular Fibrillation (chemically induced, diagnosis, physiopathology)